Compounds > n,n,n',n'-tetrakis(2-pyridylmethyl)ethylenediamine
Page last updated: 2024-11-05

n,n,n',n'-tetrakis(2-pyridylmethyl)ethylenediamine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

n,n,n',n'-tetrakis(2-pyridylmethyl)ethylenediamine has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 2 studies

N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine: a zinc ion chelating agent; structure given in first source
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine : An N-substituted diamine that is ethylenediamine in which the four amino hydrogens are replaced by 2-pyridylmethyl groups.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.

Research Excerpts

ExcerptRelevanceReference
"Acute lymphoblastic leukemia (ALL) is hematological neoplasia that affects human beings from early life to adulthood."1.72TPEN/TPGS (T2) combo dramatically reduces Philadelphia chromosome-positive pro-lymphoblastic B leukemia in BALB/c mice. ( Jimenez-Del-Rio, M; Mendivil-Perez, M; Velez-Pardo, C, 2022)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Mendivil-Perez, M2
Jimenez-Del-Rio, M2
Velez-Pardo, C2

Other Studies

2 other studies available for n,n,n',n'-tetrakis(2-pyridylmethyl)ethylenediamine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

ArticleYear
Combinational treatment of TPEN and TPGS induces apoptosis in acute lymphoblastic and chronic myeloid leukemia cells in vitro and ex vivo.
    Medical oncology (Northwood, London, England), 2022, May-17, Volume: 39, Issue:7

    Topics: Apoptosis; Child; Ethylenediamines; Humans; Jurkat Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Po

2022
TPEN/TPGS (T2) combo dramatically reduces Philadelphia chromosome-positive pro-lymphoblastic B leukemia in BALB/c mice.
    Medical oncology (Northwood, London, England), 2022, Nov-09, Volume: 40, Issue:1

    Topics: Adult; Animals; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive;

2022